As presented in subgroup analyses (Fig. 3), TDF therapy showed a significantly better effect on reducing risk of HCC recurrence in patients with following tumor characteristics: Maximum diameter plus number of viable tumor ≥ 5, with MIV or MAT, AFP at LT ≥ 20 ng/ml, and well or moderate tumor grade. Here, AFP is linked to neoplasm.